Skip to content
value.today

Avila Therapeutics Inc.

🇺🇸 Waltham, Massachusetts, USABiotechnologyFounded 2006

Formerly Conxcys, Inc.

Total raised
$28 M
2 rounds on record
Latest round
$23 M
Jul 2009
First round on record
Apr 2009
Today
Private
No later event on record

Funding rounds

2 counted as startup funding. Open the number of investors for the round's details.

Funding rounds of Avila Therapeutics Inc.
MonthRaisedRaiseSizeInvestorsSoldFiling
Jul 2009$23 MNo. 2$10 to $50 million

Avila Therapeutics Inc.: Raise no. 2, Jul 2009

Investors in this round

9 investors had bought by the notice of Jul 6, 2010: 9 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$23 M of $30 M offered; $8 M still to sell
Smallest investment taken
no minimum stated
What was sold
equity
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
Not disclosed
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in Delaware

People named in the notice

  • Katrine Bosley · Executive Officer, Director
  • Michael F. Bigham · Executive Officer, Director
  • Roy R. Lobb · Executive Officer, Director
  • Amir R. Nashat · Director
  • Bruce F. Booth · Director
  • Daniel R. Lynch · Director
  • Henry R. Skinner · Director
  • Raj R. Parekh · Director
  • Vicki R. Sato · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Katrine S. Bosley, Ceo. Newest notice filed Jul 6, 2010 (1 amendment). Read the notice at the SEC.

equitySEC
Apr 2009$5 MNo. 1$2 to $10 million

Avila Therapeutics Inc.: Raise no. 1, Apr 2009

Investors in this round

8 investors had bought by the notice of May 14, 2009: 8 accredited, none not accredited.

Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.

What the notice says

Amount sold
$5 M of $20 M offered; $15 M still to sell
Smallest investment taken
$7,206
What was sold
debt, options or other rights to buy securities
Exemption claimed
  • 06
Meant to last
a year or less
Issuer's revenue
No revenue
Sales commissions
none
Finders' fees
none
Paid to its own people
none (proceeds used for payments to executives, directors or promoters)
The company
Corporation, incorporated in De

People named in the notice

  • Daniel Lynch · Executive Officer, Director
  • Michael F. Bigham · Executive Officer, Director
  • Roy R. Lobb · Executive Officer, Director
  • Amir Nashat · Director
  • Raj Parekh · Director
  • Vicki Sato · Director

Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.

Paid to sell the round

No one: the notice names no broker or finder paid to sell it.

Signed by Nagesh Mahanthappa, VP, Corporate Development and Operations. Newest notice filed May 14, 2009. Read the notice at the SEC.

debt, optionsSEC

How it makes money#

What its filings and its own website say, sentence by sentence, each with its source.

  • Avila Therapeutics Inc. chose not to state its revenue in its newest notice of a funding round (Jul 2010).

    SEC Form D · Jul 2010

  • The industry group it chose in its notices: Biotechnology.

    SEC Form D · Jul 2010

Products and services#

No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).

Investors#

No investor of Avila Therapeutics Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.

Executives and directors

As the company named them in its notices. Directors of a funded startup are often partners of its investors.

People named by Avila Therapeutics Inc.
NameRoleNamed in
Katrine BosleyExecutive officerJul 2010
Michael F. BighamExecutive officerJul 2010
Roy R. LobbExecutive officerJul 2010
Daniel LynchExecutive officerJul 2009
Amir R. NashatDirectorJul 2010
Bruce F. BoothDirectorJul 2010
Daniel R. LynchDirectorJul 2010
Henry R. SkinnerDirectorJul 2010
Katrine BosleyDirectorJul 2010
Michael F. BighamDirectorJul 2010
Raj R. ParekhDirectorJul 2010
Roy R. LobbDirectorJul 2010
Vicki R. SatoDirectorJul 2010
Amir NashatDirectorJul 2009
Bruce BoothDirectorJul 2009
Daniel LynchDirectorJul 2009
Henry SkinnerDirectorJul 2009
Raj ParekhDirectorJul 2009
Vicki SatoDirectorJul 2009